ALLMedicine™ Adenoid Cystic Carcinoma Center
Research & Reviews 746 results
https://doi.org/10.1097/PAI.0000000000001006
Applied Immunohistochemistry & Molecular Morphology : AIMM; Sadeghi H, Saffar H et. al.
Jan 11th, 2022 - Cancer stem cells (CSCs) are a small group of cells resistant to therapy and play a major role in tumor progression, recurrence, and poor clinical outcomes of patients. This study aimed to evaluate the association of CSC markers with clinicopathol...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746899
Clinical Nuclear Medicine; Uijen MJM, Weijers JAM et. al.
Jan 11th, 2022 - Adenoid cystic carcinoma (ACC) is a rare cancer that arises from salivary glands and other secretory glands. Pulmonary metastases are frequently observed in ACC patients with metastatic disease. Previous research showed that ACC often shows high P...
https://doi.org/10.1097/RLU.0000000000003872
Clinical Nuclear Medicine; Zhao Q, Dong A et. al.
Jan 11th, 2022 - Renal metastasis from adenoid cystic carcinoma of the head and neck is uncommon. We present 99mTc-MIBI SPECT/CT and FDG PET/CT findings in a case with isolated bilateral renal metastases from adenoid cystic carcinoma of the left maxilla. The metas...
https://doi.org/10.1007/s10585-021-10145-4 10.4103/0971-5851.203513 10.1016/j.ejca.2018.11.027 10.1016/j.anndiagpath.2020.151654 10.3390/medsci7020028 10.3389/fgene.2020.00789 10.1038/nrc2439 10.1111/j.1440-169X.2011.01287.x 10.1007/s00223-016-0219-2 10.1038/leu.2012.225 10.1002/gcc.20378 10.1038/s41389-021-00309-y 10.1002/hed.25597 10.1007/s13277-016-4797-4 10.1186/1756-9966-31-100 10.1093/nar/gky354 10.1038/nprot.2013.143 10.1016/j.neo.2021.01.002 10.1016/j.jsbmb.2015.04.019 10.1007/s11064-019-02925-y 10.14806/ej.17.1.200 10.1093/bioinformatics/bts635 10.1093/bioinformatics/btt656 10.1186/s13059-014-0550-8 10.1093/nar/gkz401 10.1186/s12964-020-00559-0 10.1093/hmg/ddi312 10.1111/his.14265 10.1007/s13277-016-4956-7 10.1155/2012/937506 10.1038/s41467-019-14190-2 10.1038/ncomms12073 10.3390/ijms20184354 10.1074/jbc.REV118.002804 10.1038/onc.2017.392 10.1073/pnas.1102826108 10.1155/2014/813067 10.1111/cas.14141 10.1080/2162402X.2016.1149667 10.1016/S0002-9440(10)64080-1 10.1007/s12094-013-1009-1 10.1007/s12094-013-1010-8 10.2741/3738 10.4161/cc.10.23.18346 10.1186/bcr3580 10.1038/s41598-019-48051-1 10.1016/j.scr.2014.08.002 10.1002/mc.22934 10.1158/0008-5472 10.1021/acs.jproteome.9b00641 10.1371/journal.pone.0133280 10.1074/jbc.M113.500264 10.1002/cbf.1808 10.1038/s41388-019-0789-3 10.1038/s41598-020-63396-8 10.1038/s41389-020-0194-3 10.1016/j.cellsig.2016.04.007 10.1038/cdd.2009.94 10.1074/jbc.REV119.007759 10.1002/1878-0261.12085 10.1038/s41388-019-0905-4 10.1016/j.semcancer.2015.02.003 10.1016/j.drudis.2021.07.007 10.1007/978-3-030-43085-6_8 10.1016/j.bbamcr.2015.11.017 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q 10.1161/01.res.80.5.617 10.3389/fphys.2016.0016 10.1186/1752-0509-6-50 10.1159/000399103 10.1023/a:1006623001465 10.1016/j.canlet.2020.01.039 10.1016/j.canlet.2021.07.010 10.1158/1535-7163.MCT-16-0185 10.1182/blood-2015-09-668632 10.1016/j.exphem.2016.12.003 10.1038/leu.2017.317 10.1038/cti.2014.29 10.1111/cas.12156
Clinical & Experimental Metastasis; Říhová K, Dúcka M et. al.
Jan 8th, 2022 - The transcription factor c-Myb is an oncoprotein promoting cell proliferation and survival when aberrantly activated/expressed, thus contributing to malignant transformation. Overexpression of c-Myb has been found in leukemias, breast, colon and a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734260
BMC Ophthalmology; Makselis A, Petroska D et. al.
Jan 7th, 2022 - Acquired nasolacrimal duct obstruction is a blockage of the lacrimal outflow system usually caused by local nonspecific inflammation of the lacrimal sac and the nasolacrimal duct. However, cases exist where the primary nasolacrimal system obstruct...
Clinicaltrials.gov 18 results
https://clinicaltrials.gov/ct2/show/NCT04209660
Dec 23rd, 2021 - The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. R...
https://clinicaltrials.gov/ct2/show/NCT03691207
Dec 14th, 2021 - This is a Phase 2, non comparative, open label, multicenter study of AL101 in patients with recurrent or metastatic ACC who harbor NOTCH 1,2,3,4 activating mutations.
https://clinicaltrials.gov/ct2/show/NCT03291002
Nov 4th, 2021 - This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single a...
https://clinicaltrials.gov/ct2/show/NCT03207672
Oct 27th, 2021 - The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in par...
https://clinicaltrials.gov/ct2/show/NCT02780310
Jun 2nd, 2021 - The purpose of this study is to find out what effects, good and/or bad, the drug lenvatinib has on the patient and on adenoid cystic carcinoma. This type of cancer study is called a phase II study. Researchers hope to learn if the study drug will ...
News 13 results
https://www.onclive.com/view/dana-farber-announces-center-for-salivary-and-rare-head-and-neck-cancers
Oct 6th, 2021 - New center offers unique treatment and research opportunities largely unavailable elsewhere Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive c...
https://www.medpagetoday.com/hematologyoncology/breastcancer/92044
Apr 12th, 2021 - Certain histological subtypes of triple-negative breast cancer (TNBC) were more aggressive with worse treatment response and clinical course compared with others, researchers reported. A cohort study of 8,479 patients with rare breast cancers from...
https://www.onclive.com/view/combination-therapy-for-recurrent-endometrial-cancer
Apr 2nd, 2021 - Bradley J. Monk, MD, FACS, FACOG: Let’s transition and talk about the best treatment for second-line non–MSI [microsatellite instability]-high recurrent endometrial cancer. Katie Moore, you mentioned that pembrolizumab got accelerated approval for...
https://www.onclive.com/view/com701-shows-early-promise-as-monotherapy-and-combined-with-nivolumab-in-advanced-solid-tumors
Dec 20th, 2020 - Ryan J. Sullivan, MD COM701, a novel, first-in-class immune checkpoint inhibitor, was found to demonstrate encouraging preliminary antitumor activity and good tolerability when used as either a monotherapy and in combination with nivolumab (Opdiv...
https://www.onclive.com/view/conventional-view-may-not-apply-for-all-triplenegative-breast-cancers
Dec 20th, 2020 - Stuart J. Schnitt, MD All triple-negative breast cancers (TNBCs) are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning, said Stuart J. Schnitt, MD, during a presentation at the ...
